Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NoNO-42 in Acute Ischemic Stroke (ACT-42)
NCT06403267Phase 2Recruiting
- Sponsor
- NoNO Inc.
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NoNO-42 in ischemic stroke (2 arms), sponsored by NoNO Inc. Primary endpoint: Reducing global disability at 90 days. Started Oct 2024; status: recruiting.
02
Drugs
NoNO-42
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06403267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06403267.